A vaccine developed at The Scripps Research Institute (TSRI) to block the “high” of heroin has proven effective in non-human primates. This is the first vaccine against an opioid to pass this stage of preclinical testing.
“This validates our previous rodent data and positions our vaccine in a favorable light for anticipated clinical evaluation,” said study leader Kim Janda, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI.
This research was published recently in the Journal of the American Chemical Society. The primate experiments were led by researchers at Virginia Commonwealth University.
The vaccine works by exposing the immune system to a part of the heroin molecule’s telltale structure. This teaches the immune system to produce antibodies against heroin and its psychoactive products. The antibodies neutralize heroin molecules, blocking them from reaching the brain to cause a feeling of euphoria.
Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use. In recent years, public health officials around the world have labeled heroin use as an epidemic.
The Janda Laboratory at TSRI has been working on their heroin vaccine for over eight years; the researchers had previously tested vaccine candidates under laboratory conditions and in rodents, where the strategy proved effective for neutralizing heroin.
For the new study in rhesus monkeys, the researchers redesigned their vaccine candidate to more closely resemble heroin, with the goal of better stimulating the immune system to attack this opioid.
The researchers found that the four primates that were given three doses of this vaccine showed an effective immune response and could neutralize varying doses of heroin. This effect was most acute in the first month after vaccination but lasted for over eight months. The researchers also found no negative side effects from the vaccine.
“We believe this vaccine candidate will prove safe for human trials,” Janda said. He pointed out that the components of the vaccine have either already been approved by the FDA or have passed safety tests in previous clinical trials.
Interestingly, two of the four primates tested had been pre-vaccinated with the same vaccine candidate for a more basic pilot study seven months prior to the experiment in this study. The researchers found that these two primates showed a much higher response to the vaccine in the second round of experiments. This suggested their antibody-producing cells held an immunological “memory” of the vaccine. If this effect holds true in humans, a recovering addict would have long-term immunity to heroin.
“We were really encouraged to see the vaccine produce such lasting effects in non-human primate models,” said Bremer.
This is the first vaccine against heroin to succeed in primate models. Vaccines against other drugs of abuse have been tested in humans without first completing non-human primate trials—and failed. Bremer said the new heroin vaccine is different because the researchers took a closer look at the chemistry of the vaccine, studying how well antibodies elicited by the vaccine could bind to drug molecules. “These steps let us put our best foot forward when we went into the primate study,” Bremer said.
The researchers noted that this vaccine candidate works only against heroin and not other opioid-based pain killers or medications for treating opioid addiction or overdose, leaving those open for use in emergency medical situations and for prescription medicines and substance use disorders.
The next step in this research will be to license the vaccine to an outside company for partnering in clinical trials.
Learn more: TSRI Anti-Heroin Vaccine Found Effective in Non-Human Primates
[osd_subscribe categories=’heroin-vaccine’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “HEROIN VACCINE”‘]
The Latest on: Heroin vaccine
[google_news title=”” keyword=”heroin vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Breakthrough Vaccine Shows High Protection Against Drug-Resistant Superbug in Mice
Scientists have developed a vaccine against a notorious drug-resistant superbug, targeting molecules on its surface that are also found on other bacteria and fungi. Although only tested in mice, the ...
- Vaccines have a crucial role in tackling antimicrobial resistance
Antimicrobial resistance is a leading cause of death and disability worldwide. In 2019, it caused over 1 million deaths globally and was linked to almost 5 million.
- U.K. Tests World-First Personalized Skin Cancer Vaccine
Customized with genetic information from a patient’s own tumor, vaccines like this could one day be used against lung, kidney, bladder and colon cancer.
- World-First mRNA Vaccine For Skin Cancer Commences Landmark Phase 3 Trial
A UK man has become one of the first to receive an experimental mRNA vaccine designed to prevent recurrence of melanoma skin cancer. Steve Young, a 52-year-old musician, had a stage II melanoma ...
- Merck beats earnings forecasts as cancer drug sales boom
Merck’s stocks saw a bump on Thursday after the pharmaceutical giant reported a boom in first-quarter sales of its blockbuster cancer drug Keytruda, according to the firm’s latest earnings report.
via Google News and Bing News